|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
LipoScience, Inc. Release: Published Opinion of National Lipid Association Expert Panel Advises Testing of LDL Particle Number to Assess and Manage Cardiovascular Risk
10/6/2011 10:23:16 AM
RALEIGH, N.C.--(BUSINESS WIRE)--LipoScience, Inc., an in-vitro diagnostic company advancing patient care in cardiovascular, metabolic and other diseases using an innovative and proprietary platform based on Nuclear Magnetic Resonance (NMR) technology, today announced the publication of a consensus statement in the current issue of the Journal of Clinical Lipidology by a panel of experts in the field of clinical lipidology that was convened by the National Lipid Association (NLA), a nonprofit, multidisciplinary medical society focused on enhancing the practice of lipid management in clinical medicine. The panel recommends testing for several cardiovascular biomarkers, including LDL particle number (LDL-P), for the clinical assessment and on-treatment management of cardiovascular disease (CVD) risk.
|
|
|
|
|
|
|
|
|
|
|